We are international

IMF Announces 2002 Research Grant Recipients
IMF Announces Recipients of 2002 Brian D. Novis Research Grants

The International Myeloma Foundation is pleased to announce this year’s eight recipients of its annual Brian D. Novis Research Grant Program.

"We are very excited to have this opportunity to support additional myeloma research," said Susie Novis, president of the IMF. "The goals of the organization are education, treatment and research and we are grateful to the members of the medical community who are working in myeloma. We are proud to help fund their efforts. Furthermore, we are pleased to see such an international interest in the study of myeloma."

The IMF funds both junior and senior investigators. Junior investigators will receive funding in the amount of $40,000. Senior investigators are funded at $80,000. While IMF research grants traditionally fund one-year projects, applicants may be eligible for continued funding based on the results of a mid-year progress report.

The Brian D. Novis Research Grant Program recipients include:


Jaime Claudio
Toronto General Research Institute
Developing the second generation myeloma chip.

Michael Morgan
Hannover Medical School
Inhibiting of Ras signaling as novel therapy to combat myeloma.

Amit Nathwani
University College, London
Antiangiogenic gene therapy for the treatment of myeloma.

Atanasio Pandiella
Centro de Investigacion del Cancer
Role of novel signaling routes and c-Kit in multiple myeloma proliferation.

Klaus Podar
Dana Farber Cancer Institute
The pathyphysiological relevance of VEGF in multiple myeloma.

Ivan Van Riet
Free University Brussels
Study of homing mechanisms involved in the biology of multiple myeloma.


Herve Avet-Loiseau
CHU de Nantes
Gene expression profiles in multiple myeloma.

Elliot Epner
University of Arizona
Genetic analysis of gene deregulation in multiple myeloma.

This year’s grant recipients were selected by a 12-member committee comprised of world-renowned myeloma experts. Using a rating system developed by the National Institutes of Health (NIH), proposals are scored on a variety of criteria and then ranked. Rankings are based upon the perceived scientific value and innovative thinking behind the research project, as well as the potential benefits associated with conducting such research. One of the primary goals of the Brian D. Novis Research Grant Program is to provide seed money for innovative projects with the hope that the projects selected for IMF funding will see results so promising, they will attract additional funding for further study of the topic area.

The proposals with the best overall rankings were selected for funding. Funding for these grants comes from individual donors and is made possible through the generous contributions from myeloma patients, their families and friends. With a long history of supporting myeloma research, the IMF awarded its first Brian D. Novis Research Grant in 1994 and has awarded nearly 50 research grants to date. Created in memory of IMF founder, Brian Novis, the grants promote and support research into better treatment, management, prevention and a cure for myeloma. Past research topics funded by the IMF have included the origination of myeloma, pathogenesis of promoting bone healing, prevention of early infections, and genetic events associated with myeloma.

The grants will be formally presented in Orlando, FL, during the ASH 43rd Annual Meeting. During the ceremony, individual donors who have funded a grant in full or in large part will be on hand to meet with and help present the awards to the researchers.

For more information on the Brian D. Novis Research Grant Program, please call (800) 452-CURE.

 related articles